Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Vacc-4x

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES The REDUC clinical study Part B investigated Vacc-4x/rhuGM-CSF therapeutic vaccination prior to HIV latency reversal… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Immune priming before reversal of latency might be a component of a functional HIV cure. To assess this concept, we… Expand
Is this relevant?
2016
2016
Methods In this single-arm, phase 1B/2A trial, we recruited adults treated at the Department of Infectious Diseases, Aarhus… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2014
2014
BACKGROUND Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug… Expand
Is this relevant?
2014
2014
Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
  • Taff Jones
  • Current opinion in investigational drugs
  • 2010
  • Corpus ID: 42282854
Vacc-4x is being developed by Bionor Immuno AS as a therapeutic vaccine to be used in conjunction with antiretroviral therapies… Expand
Is this relevant?
2005
2005
We have previously shown that HIV p24-like peptides (Vacc-4x) via activation of skin dendritic cells induced immune responses in… Expand
Is this relevant?
2004
2004
OBJECTIVE The Vacc-4x immunotherapy candidate is composed of four modified peptides corresponding to conserved domains of the HIV… Expand
Is this relevant?
2002
2002
Highly active antiretroviral therapy (HAART) can effectively suppress HIV-1 replication but, as soon as the drugs are withdrawn… Expand
Is this relevant?